[1]
Bartl R.: Antiepileptika-induzierte Osteopathie.Dtsch Med Wochenschr
2007;132:1475–1479.
[2]
Verrotti A., Coppola G., Parisi P.: Bone and calcium metabolism and
antiepileptic drugs. Clinical Neurology and Neurosurgery 2009;112:1–
10.
[3]
Mintzer S.: Powikłania metaboliczne stosowania leków
przeciwpadaczkowych. Current Opinion in Neurology 2010;8:12–16.
[4]
Coppola G., Fortunato D., Auricchio G. et al: Bone mineral density
in children, adolescents, and young adults with epilepsy. Epilepsia
2009;50:2140–2146.
[5]
Sheth R.D., Harden C.L.: Sreening for bone health in epilepsy.Epilepsia
2007;48:39–41.
[6]
Beerhorst K., Huvers F.C., Renier W.O.: Severe early onset osteopenia
and osteoporosis caused by antiepileptic drugs. The Netherlands Journal
of Medicine 2005;63:222–226.
[7]
Gniatkowska-Nowakowska A.: Fractures in epilepsy children. Seizure
2010;19:324–325.
[8]
Kulak K.A., Borba V.Z., Bilezikian J.P. et al.: Bone mineral density and
serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs.
Arq Neuropsiquiatr 2004;62:940–948.
[9]
Gissel T., Poulsen C.S., Vestergaard P.: Adverse effects of antiepileptic
drugs on bone mineral density in children. Expert Opin Drug Saf
2007;6:267–278.
[10]
Farhat G., Yamout B., Mikati M.A. et al: Effect of antiepileptic drugs on
bone density in ambulatory patients. Neurology 2002;58:1348–1353.
[11]
Andress D.L., Ozuna J., Tirschwell D. et al: Antiepileptic drug-induced
bone loss in young male patients who have seizures. Arch Neurol
2002;59:781–786.
[12]
Elliott J.O., Jacobson M.P., Haneef Z.: Homocysteine and bone loss in
epilepsy. Seizure 2007;16: 21–34.
[13]
Sheth R.D., Bruce H.P.: Bone in idiopathic and symptomatic epilepsy.
Epilepsy Research 2008;78:71–76.
[14]
Babayigit A., Dirik E., Bober E. et al: Adverse effects of antiepileptic
drugs on bone mineral density. Pediatric Neurology 2006;35:177–181.
[15]
Shellhaas R.A., Joshi S.M.: Vitamin D and bone health among children
with epilepsy. Pediatric Neurology 2010;42:385–393.
[16]
Tekgul H., Serdaroglu G., Huseyinov A. et al.: Bone mineral status in
pediatric outpatients on antiepileptic drug monotherapy. J Child Neurol
2006;21:411–414.
[17]
Rieger-Wettengl G., Tutlewski B., Stabrey A. et al.: Analysis of
the musculoskeletal system in children and adolescents receiving
anticonvulsant monotherapy with valproic acid or carbamazepine.
Pediatrics 2001;108:107–110.
[18]
Vestergaard P.: Changes in bone turnover, bone mineral and fracture risk
induced by drugs used to treat epilepsy 2008;3:168–172.
[19]
Kumandas S., Koklu E., Gumus H. et al.: Effect of carbamazepine and
valproic acid on bone mineral den sity. J Pediatr Endocrinol Metab
2006;19:529–534.
[20]
Cansu A., Yesilkaya E., Serdarođlu A. et al.: Evaluation of bone
turnover in epileptic children using oxcarbazepine. Pediatric Neurology
2008;39:266–271.
[21]
Vurucu S., Gulgun M., Yesilkaya E. et al.: The effects of oxcarbazepine
treatment on vitamin B12 and folate levels, thyroid functions, sex
hormones and bone mineral density in epileptic patients. Cent Eur J Med
2009;4:310–314.
[22]
Bostanciođlu M., Öner N., Küçükuđurluođlu Y. et al.: Does valproate
therapy decrease the bone mineral density in one-year follow-up in
children. Medical Journal of Trakya University 2009.
[23]
Ecevit C., Aydođan A., Kavakli T. et al: Effect of carbamazepine and
valproate on bone mineral density. Pediatric Neurology 2004;31:279–
282.
[24]
Oner N., Kaya M., Karasalihođlu S. et al.: Bone mineral metabolism
changes in epileptic children receiving valproic acid. J Paediatr Child
Health 2004:40:470–473.
[25]
Verrotti A., Agostinelli S., Coppola G. et al.: A 12-month longitudinal study
of calcium metabolism and bone turnover during valproate monotherapy.
European Journal of Neurology 2009;17:232–237.
[26]
Lado F., Spiegel R., Masur J. et al.: Value of routine screening for bone
demineralization in an urban population of patients with epilepsy.
Epilepsy Research2008;78:155–160.
[27]
Sheth R.D., Binkley N., Hermann BP.: Progressive bone mineral deficit in
epilepsy. Neurology 2008;70:170–176.
[28]
Fuleihan G., Dib L., Yamout B. et al.: Predictors of bone density in
ambulatory patients on antiepileptic drugs. Bone 2008;43:149–155.
[29]
Sayo Y., Kondo I., Ishida S. et al.: Decreased bone mass and increased
bone turnover with valproate therapy in adults with epilepsy. Neurology
2001;57:445–449.
[30]
Noworyta-Ziętara M., Miazgowski T., Krzyżanowska-Świniarska B. et
al.: Czy otyłość chroni przed osteoporozą? Endokrynologia, Otyłość i
Zaburzenia Przemiany Materii 2008;4:69–77.
[31]
Song X.Q., Wang Z.P., Bao K.R. at al.: Effect of carbamazepin and
valproate on bone metabolism in children with epilepsy. Chinese Journal
of Pediatrics 2005;43:728–732.
Scholar Google
PubMed